NJ MAT Centers of Excellence Newsletter |
|
Friday, July 2nd, 2021 | Issue #26 |
|
|
|
Registration Requirements for Narcotic Treatment Programs (NTP) with Mobile Components |
The DEA published this final rule, effective July 28th, 2021, that will increase access to life-saving medications for opioid use disorder, particularly methadone, by waiving the requirement of a separate registration at each principal place of business or professional practice for those NTPs with mobile components fully complying with the requirements of this rule. |
|
|
|
|
Helping People Who Use Drugs Survive, Not Abstain: “Harm Reduction” Gains Federal Support |
This is a New York Times article supporting federal funds for harm reduction programs that distribute clean syringes and other supplies needed to help keep those who use drugs alive. |
|
|
|
|
ECHO: Concurrent Benzodiazepine Use Disorder and Opioid Use Disorder |
If you missed any of the previous MAT or continuous quality improvement ECHO sessions, they are posted on our Northern COE Website webinar archive. Please note that you are only able to receive CE credits by attending LIVE ECHO sessions.
The next ECHO session is on Friday, July 9th from 12 - 1pm
Topic: Managing Concurrent Benzodiazepine Use Disorder and OUD
This ECHO program will provide you some strategies that will help you to manage co-morbid benzodiazepine use disorder in patients with opioid use disorder.
Do you have a patient or client you would like to present to the panel to receive recommendations and suggestions for management? Please click here to email your question(s) or scenario(s).
|
|
|
|
|
CME Event (2nd Opportunity): Do You Need More Guidance in Buprenorphine Prescribing and Practice Implementation? |
If you were not able to join the NJ MAT Centers of Excellence for a free two-hour CME training last month focused on the how and why of buprenorphine prescribing and practice implementation, here is your next opportunity.
The live session will be held on Zoom on Wednesday, July 21st, 2021 from 9am–11am EDT.
Given the recent release of HHS' new practice guidelines regarding buprenorphine treatment for opioid use disorder, the course content now reviews all information needed to prescribe in the ED and provide clinical justification for the use of MOUD that can be applied in all settings. Faculty will also walk attendees through the SAMHSA waiver application and submission process to treat up to 30 patients.
Should you also be unable to attend this session, we will have another session on Tuesday, October 5th, 2021 from 5pm-7pm EDT.
|
|
|
|
|
MAT Lunch Hour: Cannabis Legalization/Decriminalization in NJ and Implications |
Join us for the next MAT Lunch Hour to network, collaborate, and discuss, which are now occurring monthly!
The next forum will feature Ami Kachalia of the ACLU of New Jersey, who will be speaking about cannabis legalization and decriminalization in NJ, and its implications.
Next Forum: Wednesday, July 28th, 12 - 1pm
|
|
|
|
|
A Multi-Methods and Longitudinal Study of Patients’ Perceptions in Injectable Opioid Agonist Treatment |
As part of Canada’s first injectable opioid agonist treatment (iOAT) program, the RUTH (Research on the Utilization of Therapeutic Hydromorphone) study explored the relationship of open-ended positive and negative perceptions of injectable diacetylmorphine (heroin) or hydromorphone and patient satisfaction scores collected during eight time-points over an 18-month period. Researchers analyzed the Client Satisfaction Questionnaire (CSQ-8) comments during the eight time-points and designed positive and negative perception themes. This study supports the value of open-ended comment integration with patient satisfaction questionnaire data to determine patient-centered program evaluation of substance use treatment. |
|
|
|
|
Emergency Department-Initiated Buprenorphine and Referral to Follow-up Addiction Care: A Program Description |
This is a program evaluation at a Boston, MA hospital to analyze predictors of ED-based OUD treatment and subsequent engagement. It finds that amongst the 1,946 patients who had their records reviewed in 2019, patients who received ED-OUD care were more likely to engage and retain in treatment in subsequent follow-up. Patients more likely to receive and follow-up for care, however, were those who were young, white, and male, compared to those patients who were black and Hispanic/Latinx. This program provides greater support for providing MOUD in the emergency department as a vital strategy in getting patients on and retained in treatment. |
|
|
|
|
Potential Barriers to Filling Buprenorphine and Naltrexone Prescriptions Among a Retrospective Cohort of Individuals with Opioid Use Disorder |
This is a study reviewing data from a large de-identified database linking individuals’ electronic medical records and administrative claims data to help identify those with a new diagnosis of OUD and the percentage of those who filled prescriptions for MOUD issued to them. The primary outcome was a prescription fill within 30 days. Out of the 264 individuals identified, 70% filled the prescription within 30 days, and 57% filled the prescription on the day it was written. Given the cascade of barriers for the treatment of OUD (from seeking help, getting an appointment, and to not being able to fill the prescription), ensuring that patients fill their prescription on the same-day of prescription receipt is critical. |
|
|
|
|
Medicaid Participation Among Practitioners Authorized to Prescribe Buprenorphine |
This is an article examining Medicaid participation amongst buprenorphine-waivered providers in Virginia in 2019, looking at differences between physician specialties, NPs, and physician assistants. It finds that NPs are more likely to treat any Medicaid patients compared to physicians. Amongst those who treated any Medicaid patients, the likelihood of treating a larger number of Medicaid patients was higher amongst NPs than physicians. Additionally, Medicaid participation was much higher among those with greater waiver limits. Strengthening and educating prescribers (including NPs) about the NJ OBAT Model will continue to be our goal in NJ, since this is a model specific to incentivize providers and increase quality of care for Medicaid recipients. |
|
|
|
|
Buprenorphine Waiver Tip Sheet |
Given the recent HHS guidelines that state prescribers who do NOT work in the outpatient setting OR are only intending on treating 30 or less patients, the COEs created this guide to help these prescribers obtain a waiver to prescribe buprenorphine for up to 30 patients at one time. Click below for the tip sheet. |
|
|
24/7 MAT Provider Hotline: 844-HELP OUD (844-435-7683)
|
|
|
|
|
|
|
